Efficacy and safety assessment of neoadjuvant paclitaxel and trastuzumab in Chinese women with Her-2 positive operable breast cancer.
- Author:
Ning LIAO
1
;
Guo-chun ZHANG
;
Xue-rui LI
;
Meng YAO
;
Kun WANG
;
Jian ZU
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Antibodies, Monoclonal; administration & dosage; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; adverse effects; therapeutic use; Asian Continental Ancestry Group; Breast Neoplasms; drug therapy; metabolism; pathology; Carcinoma, Ductal, Breast; drug therapy; metabolism; pathology; Female; Humans; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neutropenia; chemically induced; Paclitaxel; administration & dosage; Receptor, ErbB-2; metabolism; Remission Induction; Trastuzumab
- From: Chinese Journal of Oncology 2010;32(7):544-547
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo assess the efficacy and safety of neoadjuvant 3-weekly paclitaxel plus trastuzumab (TH) in Chinese women with Her-2 overexpressing operable breast cancer.
METHODSThis is a single center open-label phase II clinical trial. The included patients underwent 4 cycles of neoadjuvant 3-weekly TH before surgery. The primary endpoint was pathologic complete response rate (pCR rate) and the secondary endpoint was overall response rate (OR rate). Patients were also stratified according to hormone receptor status, and pCR rate and OR rate were compared between subgroups. Adverse events were graded according to CTCAE v3.0.
RESULTSThere were 40 eligible patients entering this study with median age of 49 years. All patients completed 4 cycles of neoadjuvant treatment. pCR rate was 52.5% and OR rate was 87.5%. The differences of pCR and OR rates between subgroups were of no statistical significance. No cardiac toxicity event severer than grade 2 was recorded.
CONCLUSION3-weekly TH regimen has satisfactory pCR rate and OR rate in Chinese patients with Her-2 overexpressing operable breast cancer and reliable safety.
